GENERIC
Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?
Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 crore. Revenue grew 35%, while brokerages differed on valuation concerns and future growth prospects.
For long- and medium-term investors: Cycles turn, principles don’t; 5 large-cap stocks with upside potential of up to 29%
These are the stocks that fell the most, so they may bounce back the most if the fund flows return. They are the ones FPI money will target first. And they tend to be the businesses with great track records, the ones that have been through bad patches like this before and have come out unscathed. Yes, we are talking about large-cap stocks.
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in Brazil
Dr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be available as a pre-filled, multi-dose pen in two dosages for weekly administration. This drug targets treatment for type 2 diabetes alongside diet and exercise, particularly in patient groups needing alternative therapies. Brazil's diabetes prevalence creates significant market demand, estimated at approximately $244.6 million.
Biocon CEO forecasts H2 results to outperform H1; company posts 52% fall in Q2 net profit; revenue up 2%
Biocon reported a 52% drop in second-quarter net profit due to shipment delays caused by geopolitical issues. The company expects revenue growth in the second half of fiscal 2027 from its biosimilars and insulin demand. Launches of pertuzumab in Europe and Brazil are anticipated soon, contributing to this growth. In the US market, their ustekinumab biosimilar has gained significant market share, boosting prospects.
Alkem Laboratories appoints Amrut Naik as CEO
Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.
US midterm elections: Trump approval stuck near record low as voters lean towards Democrats, poll shows
US President Donald Trump's approval rating remains low as voters indicate their intention to oppose him in upcoming elections. Polls show that 46% of voters prefer Democrats compared to 38% for Republicans. Many voters identify rising living costs as a significant issue influencing their decisions. Democratic voters express greater enthusiasm about voting compared to their Republican counterparts. The general election outcomes are expected to reflect these sentiments among the electorate.
Sun Pharma’s specialty portfolio, Organon deal to drive growth
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Time to be be cautious in the market, convinced about the business: 5 large-cap stocks with upside potential of up to 22%
This is the time to focus on businesses that have lived through storms like this before and come out the other side. The large, proven names are where quality is to be found, and they have lagged badly enough that the odds are now tilting in their favour. Just wait for the mood to finally turn.
Sun Pharma Q2 profit takes a hit on exceptional items
Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%
Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.
India’s drug pricing policy must balance affordability, medicine availability and pharma industry growth
The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussion about drug pricing and accessibility. The existing regulatory framework aims to provide affordable medicines while supporting the pharmaceutical industry. Ensuring pricing transparency and targeted interventions can help address excessive margins in the supply chain. The ultimate goal remains to enhance patients' access to quality medicines at reasonable prices.
Cancer drug price cuts leave costly brands untouched
Prices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices of top-selling patented treatments will remain unchanged after the revision by the NPPA. Generic cancer drugs will experience steep reductions, with some seeing over a 10-fold decrease in price. The Supreme Court is hearing petitions aimed at regulating high trade margins charged by hospitals.
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches. Cipla remains focused on evaluating inorganic opportunities to enhance its specialty portfolio.
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%
Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker North American sales. India revenue grew 12%, while US regulatory approval and a biosimilar partnership supported its product pipeline.
Cipla expects US business to draw support from upcoming product pipeline
Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.
Trump approval rises from record low to 32% ahead of midterm election, Reuters Ipsos poll finds
Donald Trump’s public approval rating rose by one percentage point to 32%, recovering slightly from a record low a week earlier, according to a Reuters/Ipsos poll. With the November 3 US midterm elections approaching, registered voters favoured Democrats over Republicans by 47% to 36% on the generic congressional ballot. The poll also found that Democrats led by nine percentage points after undecided voters were asked about their preferences.
Load More
